Actively Recruiting
Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment
Led by Centre for Addiction and Mental Health · Updated on 2026-03-10
150
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
Sponsors
C
Centre for Addiction and Mental Health
Lead Sponsor
K
Krembil Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the Creyos online cognitive assessment platform in older adults who have mild cognitive impairment (MCI) or major depressive disorder in remission (rMDD). This observational study aims to confirm the feasibility of using the Creyos battery in these groups and to see if it can detect cognitive changes that predict outcomes on traditional paper-and-pencil neuropsychological tests over a period of up to five years. Participants are divided into three groups: those diagnosed with MCI, individuals with remitted major depressive disorder without current symptoms, and healthy controls with no psychiatric history or psychotropic medication use. They will complete the Creyos online cognitive tests every three months and undergo yearly in-person neuropsychological testing to compare results over time. During the study, participants will be assessed quarterly with the Creyos platform and yearly with standard cognitive tests for up to five years. Researchers will monitor how well the Creyos battery works in these populations, looking at feasibility and validity of the online tests in detecting cognitive changes. The study involves regular evaluations, including cognitive assessments conducted both online and in person, with participant involvement spanning up to five years.
CONDITIONS
Brief Title
Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to read and communicate in English
- Availability of a study partner who has regular contact with the participant
- For Mild Cognitive Impairment group: aged 60 or older and meets DSM 5 criteria for Minor Neurocognitive Disorder (MCI)
- For Major Depressive Disorder in remission group: aged 65 or older and meets DSM 5 criteria for one or more major depressive episodes during adult life with specific remission timelines
- For Control group: aged 60 or older
You will not qualify if you...
- Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD
- DSM 5 diagnosis of alcohol or other substance use disorder within the past 12 months
- High risk for suicide
- Significant neurological conditions such as stroke, seizure disorder, or multiple sclerosis
- Unstable medical illnesses like uncontrolled diabetes or hypertension
- Taking anticonvulsants or psychotropic medication interfering with cognitive testing that cannot be safely stopped
- Current depressive symptoms with a MADRS score of 10 or above
- For MCI group: having taken a cognitive enhancer within the past 6 weeks
- For rMDD group: having taken a cognitive enhancer within the past 6 weeks or received electroconvulsive therapy within 6 months
- For Control group: meets DSM 5 criteria for major depressive disorder or mild cognitive impairment at any time in life
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants complete the Creyos online cognitive assessments approximately every three months to evaluate cognitive function over time.
Quarterly online assessments
Duration - Up to 5 years
Participants undergo yearly in-person cognitive testing to validate the Creyos online platform.
Annual in-person visits
Trial Site Locations
Total: 3 locations
1
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 1W8
Actively Recruiting
2
University Health Network
Toronto, Ontario, Canada, M5G 2C4
Actively Recruiting
3
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1H4
Actively Recruiting
Research Team
B
Benoit H. Mulsant, MD
H
Heather Brooks, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here